Cargando…

PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes

The novel brain-penetrant peroxisome proliferator-activated receptor gamma agonist leriglitazone, previously validated for other rare neurodegenerative diseases, is a small molecule that acts as a regulator of mitochondrial function and exerts neuroprotective, anti-oxidative and anti-inflammatory ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santambrogio, Paolo, Cozzi, Anna, Di Meo, Ivano, Cavestro, Chiara, Vergara, Cristina, Rodríguez-Pascau, Laura, Martinell, Marc, Pizcueta, Pilar, Tiranti, Valeria, Levi, Sonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862015/ https://www.ncbi.nlm.nih.gov/pubmed/36678831 http://dx.doi.org/10.3390/pharmaceutics15010202

Ejemplares similares

Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate
por: Pizcueta, Pilar, et al.
Publicado: (2023)

Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome
por: Musokhranova, Uliana, et al.
Publicado: (2023)

PKAN hiPS-Derived Astrocytes Show Impairment of Endosomal Trafficking: A Potential Mechanism Underlying Iron Accumulation
por: Ripamonti, Maddalena, et al.
Publicado: (2022)

Massive iron accumulation in PKAN-derived neurons and astrocytes: light on the human pathological phenotype
por: Santambrogio, Paolo, et al.
Publicado: (2022)

Coenzyme A corrects pathological defects in human neurons of PANK2‐associated neurodegeneration
por: Orellana, Daniel I, et al.
Publicado: (2016)

Inherited Disorders of Coenzyme A Biosynthesis: Models, Mechanisms, and Treatments
por: Cavestro, Chiara, et al.
Publicado: (2023)

Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model
por: Brunetti, Dario, et al.
Publicado: (2012)

Neuronal Ablation of CoA Synthase Causes Motor Deficits, Iron Dyshomeostasis, and Mitochondrial Dysfunctions in a CoPAN Mouse Model
por: Di Meo, Ivano, et al.
Publicado: (2020)

Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES)
por: Pandolfo, Massimo, et al.
Publicado: (2022)

Exploiting hiPSCs in Leber's Hereditary Optic Neuropathy (LHON): Present Achievements and Future Perspectives
por: Peron, Camille, et al.
Publicado: (2021)

Harmful Iron-Calcium Relationship in Pantothenate kinase Associated Neurodegeneration
por: Santambrogio, Paolo, et al.
Publicado: (2020)

"Evaluación sensorial del producto arti-pank"
por: Peralta Palacios, Miriam
Publicado: (2007)

Novel PANK2 mutation in a Chinese boy with PANK2-associated neurodegeneration: A case report and review of Chinese cases
por: Zhang, Yingying, et al.
Publicado: (2019)

Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches
por: Di Meo, Ivano, et al.
Publicado: (2015)

Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson’s disease with brain iron accumulation through pseudo-exon activation
por: Cavestro, Chiara, et al.
Publicado: (2021)

PKAN neurodegeneration and residual PANK2 activities in patient erythrocytes
por: Werning, Maike, et al.
Publicado: (2020)

Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-γ Agonists
por: Gurley, Catherine, et al.
Publicado: (2008)

Generation and Validation of an Anti-Human PANK3 Mouse Monoclonal Antibody
por: Khadka, Sunada, et al.
Publicado: (2022)

Mitochondrial Transplantation in Mitochondrial Medicine: Current Challenges and Future Perspectives
por: D’Amato, Marco, et al.
Publicado: (2023)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

PPAR-gamma agonist pioglitazone recovers mitochondrial quality control in fibroblasts from PITRM1-deficient patients
por: Di Donfrancesco, Alessia, et al.
Publicado: (2023)

Differential activation of catalase expression and activity by PPAR agonists: Implications for astrocyte protection in anti-glioma therapy()
por: Khoo, Nicholas K.H., et al.
Publicado: (2013)

HiCBin: binning metagenomic contigs and recovering metagenome-assembled genomes using Hi-C contact maps
por: Du, Yuxuan, et al.
Publicado: (2022)

A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK
por: Chiarelli, Laurent R., et al.
Publicado: (2018)

A New Allelic Variant in the PANK2 Gene in a Patient with Incomplete HARP Syndrome
por: Martos, Myriam Ley, et al.
Publicado: (2020)

Novel PANK2 Mutations in Patients With Pantothenate Kinase-Associated Neurodegeneration and the Genotype–Phenotype Correlation
por: Li, Wen-Bin, et al.
Publicado: (2022)

Gene Therapy for Mitochondrial Diseases: Current Status and Future Perspective
por: Di Donfrancesco, Alessia, et al.
Publicado: (2022)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

A Novel Nonsense Mutation in PANK2 Gene in Two Patients with Pantothenate Kinase-Associated Neurodegeneration
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2016)

Novel PANK2 mutation in the first Greek compound heterozygote patient with pantothenate-kinase-associated neurodegeneration
por: Paraskevas, George P, et al.
Publicado: (2017)

Comment on “A New Allelic Variant in the PANK2 Gene in a Patient with Incomplete HARP Syndrome”
por: Walker, Ruth Helen, et al.
Publicado: (2021)

Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels
por: Álvarez-Córdoba, Mónica, et al.
Publicado: (2022)

PI3K-PANK4: a new target for de novo synthesis of coenzyme A
por: Guan, Jizhong, et al.
Publicado: (2022)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Reprogramming of HUVECs into Induced Pluripotent Stem Cells (HiPSCs), Generation and Characterization of HiPSC-Derived Neurons and Astrocytes
por: Haile, Yohannes, et al.
Publicado: (2015)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
por: Scatena, Roberto, et al.
Publicado: (2008)

Protocol for Tri-culture of hiPSC-Derived Neurons, Astrocytes, and Microglia
por: Ryan, Sean K., et al.
Publicado: (2020)

Mitochondrial iron and energetic dysfunction distinguish fibroblasts and induced neurons from pantothenate kinase-associated neurodegeneration patients
por: Santambrogio, Paolo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tcbl1d06uiccuedhgqkeo6b7q8